Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | MMP9 | P14780 | 4/20 | 0.41 |
| ▸ | MMP2 | P08253 | 3/20 | 0.41 |
| ▸ | MMP14 | P50281 | 3/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14297325 | 0.81 | SMN1; SMN2 (0.50) | ACHESMN1; SMN2RAB9AMGLL | |
| SCHEMBL21606788 | 0.80 | GAA (0.47) | CA12CA1CA2CA9CA14 | |
| SCHEMBL19252360 | 0.79 | FAAH (0.38) | CA12CA1CA2CA9CA14 | |
| SCHEMBL5105043 | 0.79 | RAB9A (0.50) | MAPTSMN1; SMN2RAB9A | |
| SCHEMBL23144700 | 0.78 | SMN1; SMN2 (0.46) | CA12CA1CA2CA9CA14 | |
| SCHEMBL23144701 | 0.78 | PTGDR2 (0.43) | CA12CA1CA2CA9CA14 | |
| SCHEMBL4027417 | 0.78 | MGLL (0.64) | MAPTPKMSMN1; SMN2RAB9AMGLL | |
| SCHEMBL11577938 | 0.77 | ADAMTS4 (0.52) | PTGS2MMP9MMP2MMP14ACHE | |
| SCHEMBL19332035 | 0.77 | SMN1; SMN2 (0.50) | PTGS2ACHESMN1; SMN2RAB9AMGLL | |
| SCHEMBL23144838 | 0.75 | CA12 (0.41) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213062-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2022-07-07 | — | — | US | disclosed |
| US-11339141-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210002252-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-10640485-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190119249-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2019-04-25 | — | — | US | disclosed |
| EP-3416638-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2018-12-26 | — | — | EP | disclosed |
| US-10138219-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170240525-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | disclosed |
| WO-2017143291-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240525-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CA12 3754/4885CA1 2828/4885CA2 3501/4885 |
| US-11339141-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | CA12 3754/4885CA1 2828/4885CA2 3501/4885 |
| US-20220213062-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CA12 3754/4885CA1 2828/4885CA2 3501/4885 |
| US-20190119249-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CA12 3754/4885CA1 2828/4885CA2 3501/4885 |
| US-10640485-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | CA12 3754/4885CA1 2828/4885CA2 3501/4885 |
| US-20210002252-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CA12 3754/4885CA1 2828/4885CA2 3501/4885 |
| US-10138219-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | CA12 3754/4885CA1 2828/4885CA2 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.